Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company's product pipeline consists of a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin(R) in KRAS-mutated metastatic colorectal cancer; a Phase 2 study of onvansertib in combination with Zytiga(R) in Zytiga-resistant metastatic castration-resistant prostate cancer; and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia. Cardiff Oncology Inc., formerly known as Trovagene Inc., is based in SAN DIEGO.
| Revenue (Most Recent Fiscal Year) | $0.68M |
| Net Income (Most Recent Fiscal Year) | $-45.43M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 431.06 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.58 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -8308.50% |
| Net Margin (Trailing 12 Months) | -8308.50% |
| Return on Equity (Trailing 12 Months) | -76.45% |
| Return on Assets (Trailing 12 Months) | -62.85% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.22 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.22 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.86 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.20 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.95 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.92 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 66.53M |
| Free Float | 61.40M |
| Market Capitalization | $253.46M |
| Average Volume (Last 20 Days) | 1.01M |
| Beta (Past 60 Months) | 1.61 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.70% |
| Percentage Held By Institutions (Latest 13F Reports) | 16.29% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |